We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 08, 2022

Thromboprophylaxis After Hospitalization for COVID-19

The Lancet

 

Additional Info

The Lancet
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
Lancet 2021 Dec 15;[EPub Ahead of Print], E Ramacciotti, L Barile Agati, D Calderaro, VCR Aguiar, AC Spyropoulos, CCC de Oliveira, J Lins Dos Santos, GG Volpiani, ML Sobreira, EE Joviliano, MS Bohatch Júnior, BAL da Fonseca, MS Ribeiro, C Dusilek, K Itinose, SMV Sanches, K de Almeida Araujo Ramos, NF de Moraes, PFGMM Tierno, ALML de Oliveira, A Tachibana, RC Chate, MVB Santos, BB de Menezes Cavalcante, RCR Moreira, C Chang, A Tafur, J Fareed, RD Lopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading